| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.031 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.047 | 0.3 |